Literature DB >> 18670322

Vestibular schwannoma quantitative polymerase chain reaction expression of estrogen and progesterone receptors.

Andrew K Patel1, Thomas H Alexander, Ali Andalibi, Allen F Ryan, Joni K Doherty.   

Abstract

OBJECTIVES/HYPOTHESIS: Determine the role of estrogen receptor (ER) and progesterone receptor (PR) expression in sporadic and neurofibromatosis 2 (NF2)-related vestibular schwannomas (VS). Growth and proliferation signaling in human VS tumorigenesis may play a key role in molecular therapeutic targeting. VS carry mutations of the NF2 gene encoding the tumor suppressor, merlin, which interacts with ErbB2 in Schwann cells, implicating ErbB receptors in VS tumorigenesis. ErbB receptor family members are overexpressed or constitutively activated in many human tumors, and are effective therapeutic targets in some human cancers. VS occur more frequently in women and are larger, more vascular, and demonstrate increased growth rates during pregnancy. ER and PR may play a role in ErbB pathway activation and VS progression. STUDY
DESIGN: Quantitative real-time polymerase chain reaction (qRT-PCR) for ER and PR messenger RNA was performed using greater auricular and vestibular nerve controls (n = 8), sporadic VS (n = 23), and NF2-related VS (n = 16) tissues.
METHODS: The qRT-PCR data were normalized with standardization to a single constitutively expressed control gene, human cyclophylin.
RESULTS: Reverse transcription of messenger RNA from control and tumor specimens followed by RT Q-PCR demonstrated differences in ER and PR gene expression between sporadic and NF2-related VS.
CONCLUSIONS: ER and PR expression in VS might have implications for development of a VS-specific drug delivery system using antihormone and ErbB pathway small molecule inhibitors, due to crosstalk between these receptors. These signals may be critical for re-establishing ErbB-mediated cell density dependent growth inhibition.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18670322      PMCID: PMC3570025          DOI: 10.1097/MLG.0b013e318177e20b

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  31 in total

1.  Growth rate characteristics of acoustic neuromas associated with neurofibromatosis type 2.

Authors:  M M Abaza; E Makariou; M Armstrong; A K Lalwani
Journal:  Laryngoscope       Date:  1996-06       Impact factor: 3.325

2.  Acoustic neuroma in the last months of pregnancy.

Authors:  J Allen; R Eldridge; T Koerber
Journal:  Am J Obstet Gynecol       Date:  1974-06-15       Impact factor: 8.661

Review 3.  Progesterone synthesis and myelin formation in peripheral nerves.

Authors:  M Schumacher; R Guennoun; G Mercier; F Désarnaud; P Lacor; J Bénavides; B Ferzaz; F Robert; E E Baulieu
Journal:  Brain Res Brain Res Rev       Date:  2001-11

Review 4.  Natural history of acoustic neuromas.

Authors:  S I Rosenberg
Journal:  Laryngoscope       Date:  2000-04       Impact factor: 3.325

5.  The proliferative activity of neurilemomas.

Authors:  K S Lee; T Nagashima; K G Cho; T J Mampalam; L H Pitts; T Hoshino
Journal:  Surg Neurol       Date:  1989-12

6.  Sex hormone receptors in intracranial tumours and normal brain.

Authors:  I R Whittle; R A Hawkins; J D Miller
Journal:  Eur J Surg Oncol       Date:  1987-08       Impact factor: 4.424

7.  Steroid receptors in human brain and spinal cord tumors.

Authors:  J A Kornblum; J W Bay; M K Gupta
Journal:  Neurosurgery       Date:  1988-08       Impact factor: 4.654

8.  Expression of steroid receptors in acoustic neuroma.

Authors:  R Filipo; E Petrangeli; S Monini; F Ortolani; A Gulino; M Barbara; L Frati
Journal:  Clin Otolaryngol Allied Sci       Date:  1995-10

9.  Expression and clinical significance of Ki-67, oestrogen and progesterone receptors in acoustic neuroma.

Authors:  S Cafer; I Bayramoglu; N Uzum; M Yilmaz; L Memis; K Uygur
Journal:  J Laryngol Otol       Date:  2007-08-01       Impact factor: 1.469

10.  Estrogen and progestin receptors in acoustic and spinal neurilemmomas. Clinicopathologic correlations.

Authors:  T M Markwalder; E Waelti; R V Markwalder
Journal:  Surg Neurol       Date:  1986-08
View more
  7 in total

1.  Estrogen receptor expression in sporadic vestibular schwannomas.

Authors:  Carrie M Brown; Zana K Ahmad; Allen F Ryan; Joni K Doherty
Journal:  Otol Neurotol       Date:  2011-01       Impact factor: 2.311

2.  Incidence of vestibular schwannomas in the United States.

Authors:  Varun R Kshettry; Jason K Hsieh; Quinn T Ostrom; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  J Neurooncol       Date:  2015-05-30       Impact factor: 4.130

3.  Preclinical validation of anti-nuclear factor-kappa B therapy to inhibit human vestibular schwannoma growth.

Authors:  Sonam Dilwali; Martijn C Briët; Shyan-Yuan Kao; Takeshi Fujita; Lukas D Landegger; Michael P Platt; Konstantina M Stankovic
Journal:  Mol Oncol       Date:  2015-03-31       Impact factor: 6.603

4.  Hormones and Vestibular Disorders: The Quest for Biomarkers.

Authors:  Rhizlane El Khiati; Brahim Tighilet; Stephane Besnard; Christian Chabbert
Journal:  Brain Sci       Date:  2022-05-02

5.  Nonsteroidal sulfamate derivatives as new therapeutic approaches for Neurofibromatosis 2 (NF2).

Authors:  Yu-Chi Shen; Caroline Arellano-Garcia; Rosa E Menjivar; Ethan M Jewett; Wolfgang Dohle; Sofiia Karchugina; Jonathan Chernoff; Barry V L Potter; Kate F Barald
Journal:  BMC Pharmacol Toxicol       Date:  2019-11-15       Impact factor: 2.483

6.  Computational repositioning and preclinical validation of mifepristone for human vestibular schwannoma.

Authors:  Jessica E Sagers; Adam S Brown; Sasa Vasilijic; Rebecca M Lewis; Mehmet I Sahin; Lukas D Landegger; Roy H Perlis; Isaac S Kohane; D Bradley Welling; Chirag J Patel; Konstantina M Stankovic
Journal:  Sci Rep       Date:  2018-04-03       Impact factor: 4.379

7.  Cervical schwannoma in the early stage of pregnancy: a case report.

Authors:  Koki Kawaguchi; Koji Akeda; Norihiko Takegami; Tatsuya Kurata; Kuniaki Toriyabe; Tomoaki Ikeda; Akihiro Sudo
Journal:  BMC Surg       Date:  2020-10-20       Impact factor: 2.102

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.